BNB$749.27+0.47%BRENT$98.4+1.28%BTC$78,624-0.09%COPPER$6.69+0.65%DJI$53,414-0.51%DOGE$0.0897-0.11%DXY98.72-0.46%ETH$2,475-0.17%GOLD$4,409+0.09%NDX$29,544+0.21%SILVER$66.2+0.10%SOL$103.04+0.00%SPX$7,719-0.38%US10Y4.78+0.00%VIX15.30+5.30%BNB$749.27+0.47%BRENT$98.4+1.28%BTC$78,624-0.09%COPPER$6.69+0.65%DJI$53,414-0.51%DOGE$0.0897-0.11%DXY98.72-0.46%ETH$2,475-0.17%GOLD$4,409+0.09%NDX$29,544+0.21%SILVER$66.2+0.10%SOL$103.04+0.00%SPX$7,719-0.38%US10Y4.78+0.00%VIX15.30+5.30%
MoneyMarket365.comReal-time markets + AI-ranked and AI-analyzed financial news
·Confidence 90%

Novartis Drug Setback Heightens Competition for Amgen, Eli Lilly

Key takeaways

  • Novartis' recent failure in cholesterol drug development intensifies the competitive landscape for Amgen and Eli Lilly in reducing heart attack risks.
#Pharmaceuticals#Healthcare#Biotechnology

Analysis

Novartis' recent failure in cholesterol drug development intensifies the competitive landscape for Amgen and Eli Lilly in reducing heart attack risks.

0 likes · 0 dislikes

Comments & Replies

with Google or GitHub to join the discussion.

  • No comments yet be the first to share your view.